Details

Autor(en) / Beteiligte

• Steckelings, Ulrike M
• Paulis, Ludovit
• Namsolleck, Pawel
• Unger, Thomas

Titel

AT2 receptor agonists: hypertension and beyond

Ist Teil von

• Current opinion in nephrology and hypertension, 2012-03, Vol.21 (2), p.142-146

Ort / Verlag

England: Lippincott Williams & Wilkins, Inc

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• PURPOSE OF REVIEWResearch about the angiotensin AT2 receptor (AT2R) has been hampered in the past by the lack of a specific and selective agonist with in-vivo stability. Such an eagerly awaited agonist, compound 21, has recently become available, giving momentum to AT2R research which so far has resulted in 14 original publications. This article is intending to review those publications which address AT2R function by direct in-vivo stimulation instead of indirect approaches such as receptor blockade or genetic alteration of AT2R expression. RECENT FINDINGSStudies reviewed in this article looked at the effect of AT2R stimulation in disease models of hypertension, renal disease, stroke, Alzheimerʼs disease and myocardial infarction. AT2R stimulation does not have an antihypertensive effect, but promoted tissue protection in all models in which it was tested. Antiinflammation and antiapoptosis seem important features of the AT2R underlying improved outcome in experimental disease models. SUMMARYAvailability of nonpeptidic, orally active AT2R agonists will facilitate future AT2R research and hopefully contribute to the clarification of many still open questions regarding AT2R signalling and function. Furthermore, AT2R agonists represent a potential novel class of drugs and are expected to enter a phase I clinical study in 2012.